Autoimmune hemolytic anemia (AIHA) is a condition in which your immune system mistakenly produces antibodies that attack and destroy your own red blood cells faster than your bone marrow can replace them. The result is anemia, often with fatigue, pallor, and sometimes jaundice as the breakdown products of destroyed red cells accumulate. While it responds well to first-line treatment in most cases, AIHA comes in several distinct forms that behave differently, require different therapies, and carry underappreciated risks beyond anemia alone.
How the Immune System Turns on Its Own Red Blood Cells
In AIHA, your body produces autoantibodies that latch onto proteins on the surface of your red blood cells, flagging them for destruction. The specific type of antibody involved and the temperature at which it becomes active determine what kind of AIHA you have, and that distinction matters a great deal for treatment.
The most common form, warm AIHA, accounts for roughly two-thirds to three-quarters of all cases. It involves IgG antibodies that bind to red blood cells at normal body temperature, typically recognizing a portion of a red-cell membrane protein called band 3.1PubMed Central. Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management Once coated with these antibodies, the red cells are spotted by immune cells in the spleen and liver, which engulf and destroy them. This process is called extravascular hemolysis because the red cells are broken down inside organs rather than bursting apart in the bloodstream.
Cold agglutinin disease works through a completely different mechanism. Here, IgM antibodies bind to red blood cells at temperatures below body temperature, which is why symptoms tend to flare with cold exposure. These IgM antibodies activate the complement system, a chain of proteins that can punch holes in cell membranes or tag cells for destruction. The hemolysis in cold agglutinin disease is entirely complement-dependent, driven by activation of the classical complement pathway and the destruction of red cells coated with complement protein C3b.2PubMed Central. Cold agglutinin disease IgM antibodies circulate as large ring-shaped structures, and upon binding to red cells they change shape in a way that activates the first complement protein, C1q. A particular form of IgM, the hexameric type lacking a component called a J-chain, activates complement and destroys red cells more efficiently and has been found in significant amounts in patients with cold agglutinin disease.3Haematologica. Complement inhibitors to treat IgM-mediated autoimmune hemolysis
A less common mixed type involves both warm and cold antibodies simultaneously, and there is also a rare form called paroxysmal cold hemoglobinuria in which a specific antibody binds at cold temperatures but causes red cell destruction at body temperature. Each type has distinct treatment implications.
What Causes AIHA
About half of all warm AIHA cases are considered primary or idiopathic, meaning no clear underlying cause is identified. The immune system simply begins targeting red cells for reasons that remain poorly understood. The other half are secondary, triggered or accompanied by an identifiable condition.
The most common triggers and associations include:
- Lymphoproliferative disorders: Chronic lymphocytic leukemia (CLL) is a particularly strong association, with AIHA developing in roughly 7 to 10% of CLL patients.4PubMed Central. Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review Other lymphomas and immune disorders can also serve as a backdrop for AIHA.5Haematologica. Chronic lymphocytic leukemia and autoimmunity: a systematic review
- Other autoimmune diseases: Lupus, rheumatoid arthritis, and other systemic autoimmune conditions can coexist with AIHA. When AIHA appears alongside immune-mediated low platelet counts (immune thrombocytopenia), the combination is called Evans syndrome, a particularly challenging condition to manage.6PubMed Central. Diagnostic and Therapeutic Strategies in Evans Syndrome: A Case Report and Literature Review
- Infections: In children especially, cold agglutinin syndrome can be triggered by infections. Mycoplasma pneumoniae, a common cause of walking pneumonia, is a well-documented trigger.7Karnataka Paediatric Journal. Cold agglutinin syndrome in paediatric practice: A case series Viral infections, including Epstein-Barr virus and cytomegalovirus, can also provoke it. Post-infectious cases in children often resolve on their own once the underlying infection clears.
- Medications: Drug-induced immune hemolytic anemia is rare but potentially serious. The antibiotics most frequently implicated include certain cephalosporins (particularly cefotetan and ceftriaxone) and piperacillin.8PubMed. Drug-induced immune hemolytic anemia Penicillins and cephalosporins as a class are the most commonly involved drug families.9PubMed Central. Drug-Induced Immune Hemolytic Anemia due to Amoxicillin-Clavulanate: A Case Report and Review Stopping the offending drug is often sufficient for recovery, though severe cases may need additional treatment.
How AIHA Is Diagnosed
The diagnostic process usually starts when routine blood work reveals unexplained anemia with signs that red blood cells are being destroyed rather than simply underproduced. Several lab markers point toward hemolysis: the reticulocyte count rises as the bone marrow tries to compensate, lactate dehydrogenase goes up (a marker of cell breakdown), haptoglobin drops (because it gets used up mopping up free hemoglobin), and unconjugated bilirubin rises as the body processes the debris from destroyed red cells.10PubMed Central. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia To confirm that the hemolysis is autoimmune in nature rather than caused by something else, the key test is the direct antiglobulin test, commonly known as the Coombs test.
The Coombs test detects antibodies or complement proteins stuck to the surface of your red blood cells. It can be performed using several methods with varying sensitivity and can help distinguish between warm, cold, and mixed forms of AIHA, each of which calls for a different treatment approach.11PubMed. DAT-Negative Autoimmune Hemolytic Anemia In warm AIHA, the test typically shows IgG antibodies or complement protein C3d, or both, coating the red cells. In cold agglutinin disease, complement proteins alone are usually detected. In one study of warm AIHA patients, the average hemoglobin at presentation was about 6.4 g/dL, well below the normal range, with a reticulocyte count averaging about 7.6%, reflecting the marrow’s frantic effort to replace destroyed cells.12PubMed. Influence of immunohematological markers on severity of in vivo hemolysis in human warm autoimmune haemolytic anemia
When the Coombs Test Is Negative
Here is where diagnosis gets tricky. A small but real fraction of patients with clinical AIHA test negative on the standard Coombs test. This does not mean they don’t have the disease. The standard test simply may not be sensitive enough to detect very low levels of antibody on the red cell surface, or the antibodies involved may be of an unusual type (like IgA or low-affinity IgG) that the standard reagents miss. One diagnostic algorithm classified DAT-negative AIHA into six subtypes and achieved 97% sensitivity and 84% specificity when testing was performed before treatment began.13PubMed. Diagnostic algorithm for classification and characterization of direct antiglobulin test-negative autoimmune hemolytic anemia with 1-year clinical follow-up More sensitive techniques like flow cytometry, immunoblotting, and specialized gel-based methods can pick up what the conventional test misses.14PubMed. Western immunoblotting as a new tool for investigating direct antiglobulin test-negative autoimmune hemolytic anemias These advanced tests are available at only a handful of specialized labs, which means DAT-negative AIHA often faces delayed diagnosis and sometimes inappropriate treatment while clinicians puzzle over the discrepancy between lab results and the patient’s clinical picture.
First-Line Treatment for Warm AIHA
Corticosteroids remain the standard first-line therapy for warm AIHA. They work by broadly dampening the immune response, reducing the production of the offending autoantibodies and slowing the destruction of red cells. They are effective in about 70 to 85% of patients.15PubMed Central. Treatment of autoimmune hemolytic anemias One study found that starting steroids intravenously yielded a response rate above 80%, compared to about 42% for patients started on oral steroids, suggesting that the initial route of delivery can make a meaningful difference in how quickly the disease responds.16PubMed. Systemic corticosteroids in the treatment of warm autoimmune hemolytic anemia: A clinical setting perspective
The catch with steroids is that they need to be tapered slowly over six to twelve months, and many patients either relapse during the taper or become dependent on an unacceptably high dose to keep the disease in check. International consensus recommendations advise adding rituximab, a drug that targets and depletes a type of immune cell called B cells, early in severe cases and whenever the response to steroids alone is sluggish.17PubMed. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting Rituximab has shown efficacy both as a first-line add-on and in relapsed settings, with a favorable safety profile compared to prolonged high-dose steroids.18PubMed Central. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia
For patients who fail both steroids and rituximab, splenectomy (surgical removal of the spleen) remains an option. The spleen is the main site where antibody-coated red cells are destroyed, so removing it can stop the bleeding of red cells. Laparoscopic splenectomy achieved complete remission in 81% of patients at a median follow-up of about three years, even in patients over 60.19PubMed Central. Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia However, splenectomy carries lifelong risks including increased susceptibility to certain infections, so it tends to be reserved for refractory cases.
Treating Cold Agglutinin Disease Differently
Cold agglutinin disease does not respond well to steroids or splenectomy because the primary destruction pathway runs through the complement system rather than through splenic macrophages. Avoiding cold exposure is a basic but genuinely important part of management. Rituximab is used as part of first- and second-line treatment for cold agglutinin disease, but historically results have been modest and relapses common.
The landscape shifted with sutimlimab, a monoclonal antibody that blocks C1s, one of the early proteins in the classical complement pathway. By interrupting complement activation at its source, sutimlimab stops the cascade that destroys red blood cells while leaving the alternative and lectin complement pathways intact, preserving some of the body’s infection-fighting capacity.20PubMed. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? In the phase III CADENZA trial, 73% of patients receiving sutimlimab met the composite endpoint of improved hemoglobin, avoidance of transfusion, and avoidance of additional therapies, compared to 15% on placebo.21PubMed. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis
Long-term follow-up from the open-label extension of CADENZA confirmed sustained benefit. Over roughly two years of treatment, average hemoglobin levels rose from about 9.3 g/dL at baseline to 11 g/dL or above, bilirubin levels (a marker of red cell destruction) dropped substantially, and fatigue scores improved.22The Lancet. Long-term efficacy and safety of sutimlimab in patients with cold agglutinin disease: results from the open-label extension of the phase 3 CADENZA study One important caveat: when sutimlimab was stopped for a nine-week washout period, hemolytic markers returned toward baseline, suggesting the drug controls but does not cure the underlying disease. Patients likely need ongoing treatment.
Blood Transfusions in AIHA Are Complicated
You might think that giving blood to an anemic patient would be straightforward, but AIHA makes transfusion unusually tricky. The autoantibodies coating the patient’s red cells can also react with donor red cells, making it difficult for the blood bank to find compatible blood. Cross-matching often shows apparent incompatibility with every unit tested, which can create dangerous delays.
Guidelines are clear that emergency blood transfusion should not be withheld in life-threatening situations, even when a perfect match cannot be found.23PubMed Central. Autoimmune haemolytic anaemia: emergency blood transfusion The risk of severe anemia going untreated generally outweighs the risk of a transfusion reaction. Over time, transfusion practices in AIHA have improved considerably. Over recent decades, the rate of red blood cell transfusions dropped from about 53% to 20% of patients, and the rate of alloimmunization (developing antibodies against donor blood) fell from about 30% to 6%, thanks to better matching techniques and more conservative transfusion thresholds.24PubMed. Transfusions in autoimmune hemolytic anemias: Frequency and clinical significance of alloimmunization
The Blood Clot Risk That Often Gets Overlooked
One of the most dangerous but under-recognized complications of AIHA is an increased risk of blood clots. The hemolysis itself promotes a pro-clotting state through several mechanisms: free hemoglobin released from destroyed red cells can scavenge nitric oxide (which normally keeps blood vessels relaxed), damaged red cell membranes release particles that activate the clotting cascade, and systemic inflammation further tips the balance.
In one study of warm AIHA patients, 23% experienced at least one venous blood clot during follow-up, and the vast majority of these clots occurred during active hemolysis, often within the first two months of diagnosis.25PLoS ONE. Venous thromboembolic events during warm autoimmune hemolytic anemia That is a strikingly high rate. Yet no formal guidelines currently exist for clot prevention in AIHA patients.26PubMed Central. Autoimmune Hemolytic Anemia and Pulmonary Embolism: An Association to Consider Experts have proposed that clinicians should maintain a high level of suspicion for blood clots during active AIHA flares and consider prophylactic blood thinners while hemolysis is ongoing, including after hospital discharge.27PubMed Central. Thrombotic Complications in Patients with Immune-Mediated Hemolysis If you have AIHA and develop sudden leg swelling, chest pain, or shortness of breath, it warrants immediate medical evaluation.
Fatigue in AIHA Goes Beyond Low Hemoglobin
Patients with AIHA consistently describe fatigue as their most prominent and most bothersome symptom.28PubMed Central. Content validity and meaningful change for the FACIT-Fatigue scale in warm autoimmune hemolytic anemia: results from qualitative interview studies with patients A qualitative study of warm AIHA patients found that about four in five reported anxiety or fear, roughly three-quarters had difficulty climbing stairs, needed help from others, or had reduced physical strength, and more than half reported impacts on their social lives.29PubMed Central. Exploring patients’ experiences with wAIHA and the content validity of the FACIT-fatigue: a qualitative interview study The disease exerts a toll on emotional well-being, independence, and daily functioning that goes well beyond what you might expect from anemia alone.
Interestingly, research from a phase 2b clinical trial found only a weak-to-moderate correlation between fatigue scores and hemoglobin levels, while the correlation between fatigue and inflammatory markers was moderate to strong. This suggests that chronic inflammation, not just the anemia itself, drives a substantial portion of the exhaustion patients feel.30Blood. Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2) That finding has practical implications: simply correcting the hemoglobin level with transfusions may not fully relieve fatigue, and therapies that address the underlying immune dysregulation could offer better symptom relief.
AIHA During Pregnancy
AIHA during pregnancy carries heightened risks for both the mother and baby. In one tertiary care hospital series, every pregnant patient with AIHA experienced at least one complication during pregnancy: about 44% developed preeclampsia, 38% had babies with restricted growth, and half the babies were born preterm and required intensive care.31PubMed Central. Autoimmune Hemolytic Anaemias in Pregnancy: Experience in a Tertiary Care Hospital in South India There was no maternal death in this series, but 83% of the patients needed additional medications beyond standard prenatal care.
One important distinction during pregnancy concerns the type of antibody involved. IgG antibodies can cross the placenta, which means warm AIHA antibodies could potentially affect the baby’s red cells. IgM antibodies, as in cold agglutinin disease, cannot cross the placental barrier, but the interaction between complement activation and the clotting system may still lead to adverse outcomes for the pregnancy.32PubMed. Autoimmune hemolytic anemia in pregnancy: a challenge for maternal and fetal follow-up Management requires close collaboration between hematologists and obstetricians, with careful attention to hemoglobin levels, antibody types, and fetal growth monitoring throughout pregnancy.
Emerging Therapies and Ongoing Challenges
Despite advances, AIHA treatment remains a work in progress. Traditional first-line therapy with steroids and rituximab carries real drawbacks: prolonged steroid use brings weight gain, bone loss, diabetes risk, and mood disturbances, while relapses are common across all treatment lines. Some patients remain refractory to everything currently available.33PubMed Central. Development of New Drugs for Autoimmune Hemolytic Anemia The approval of sutimlimab for cold agglutinin disease marked a shift toward targeted therapy, and several other approaches are in clinical development.
New drug classes being studied include Bruton’s tyrosine kinase (BTK) inhibitors like rilzabrutinib, which target signaling within B cells and other immune cells involved in antibody production and red cell destruction. Other strategies focus on blocking the phagocytosis step, preventing immune cells from engulfing antibody-coated red cells even when the antibodies are still present. Complement inhibitors beyond sutimlimab are also being evaluated for both warm and cold forms. Plasma cell-directed therapies, which go after the antibody-producing factories rather than the B cells that give rise to them, represent yet another angle of attack.
When Dogs Get AIHA
AIHA is not exclusively a human problem. Dogs develop immune-mediated hemolytic anemia (IMHA) with surprising frequency, and it is one of the more dangerous conditions seen in veterinary medicine. The disease causes severe anemia and carries considerable risk of complications and death. Treatment parallels human medicine in many ways, relying on immunosuppressive drugs and blood-clot prevention, but little consensus exists among veterinarians on the optimal drug regimen.34PubMed Central. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs Certain breeds appear predisposed, including Cocker Spaniels and Irish Setters. If your dog suddenly becomes lethargic, develops pale gums, or produces dark-colored urine, IMHA is one of the conditions a veterinarian will want to rule out quickly. As in humans, thrombotic complications are a major concern, and anticoagulant therapy is part of the management discussion.